Literature DB >> 30783003

Synergistic Effect of Ceftazidime-Avibactam with Meropenem against Panresistant, Carbapenemase-Harboring Acinetobacter baumannii and Serratia marcescens Investigated Using Time-Kill and Disk Approximation Assays.

Juliana Januário Gaudereto1, Lauro Vieira Perdigão Neto1, Gleice Cristina Leite1, Roberta Ruedas Martins1, Gladys Villas Boas do Prado1, Flavia Rossi2, Thais Guimarães3, Anna Sara Levin1, Silvia Figueiredo Costa4.   

Abstract

Susceptibility of ceftazidime-avibactam and in vitro synergy with meropenem were investigated using disk approximation and time-kill assays against 11 multiresistant Acinetobacter baumannii isolates harboring oxacillinases and 5 Serratia marcescens isolates carrying bla KPC-2 Ceftazidime-avibactam was very active and synergistic with meropenem against multiresistant S. marcescens isolates. On the other hand, only the A. baumannii isolates coharboring bla OXA-23 and bla OXA-117 displayed synergy. The disk approximation technique presented good sensitivity for synergism in S. marcescens infection.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Acinetobacter baumanniizzm321990; Serratia marcescenszzm321990; ceftazidime-avibactam; disk approximation; time kill

Year:  2019        PMID： 30783003      PMCID： PMC6496051          DOI： 10.1128/AAC.02367-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis.

Authors:  Peter J Petersen; Ponpen Labthavikul; C Hal Jones; Patricia A Bradford
Journal:  J Antimicrob Chemother       Date:  2006-01-23       Impact factor: 5.790

2.  In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients.

Authors:  Robert K Flamm; Wright W Nichols; Helio S Sader; David J Farrell; Ronald N Jones
Journal:  Int J Antimicrob Agents       Date:  2016-02-03       Impact factor: 5.283

3.  Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.

Authors:  Elizabeth Temkin; Julian Torre-Cisneros; Bojana Beovic; Natividad Benito; Maddalena Giannella; Raúl Gilarranz; Cameron Jeremiah; Belén Loeches; Isabel Machuca; María José Jiménez-Martín; José Antonio Martínez; Marta Mora-Rillo; Enrique Navas; Michael Osthoff; Juan Carlos Pozo; Juan Carlos Ramos Ramos; Marina Rodriguez; Miguel Sánchez-García; Pierluigi Viale; Michel Wolff; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

4.  In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.

Authors:  Paolo Gaibani; Russell E Lewis; Silvia L Volpe; Maddalena Giannella; Caterina Campoli; Maria Paola Landini; PierLuigi Viale; Maria Carla Re; Simone Ambretti
Journal:  Int J Infect Dis       Date:  2017-09-22       Impact factor: 3.623

5.  Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?

Authors:  Cristina García-Salguero; Iciar Rodríguez-Avial; Juan J Picazo; Esther Culebras
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

6.  Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia.

Authors:  Jose F Camargo; Jacques Simkins; Thiago Beduschi; Akin Tekin; Laura Aragon; Armando Pérez-Cardona; Clara E Prado; Michele I Morris; Lilian M Abbo; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2015-10       Impact factor: 5.191

7.  Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Ryan K Shields; Brian A Potoski; Ghady Haidar; Binghua Hao; Yohei Doi; Liang Chen; Ellen G Press; Barry N Kreiswirth; Cornelius J Clancy; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2016-09-13       Impact factor: 9.079

Review 8.  Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.

Authors:  Roopali Sharma; Tae Eun Park; Stanley Moy
Journal:  Clin Ther       Date:  2016-03-02       Impact factor: 3.393

9.  Antimicrobial Combinations against Pan-Resistant Acinetobacter baumannii Isolates with Different Resistance Mechanisms.

Authors:  Gleice Cristina Leite; Maura Salaroli Oliveira; Lauro Vieira Perdigão-Neto; Cristiana Kamia Dias Rocha; Thais Guimarães; Camila Rizek; Anna Sara Levin; Silvia Figueiredo Costa
Journal:  PLoS One       Date:  2016-03-21       Impact factor: 3.240

10.  Analyses of a Ceftazidime-Avibactam-Resistant Citrobacter freundii Isolate Carrying bla KPC-2 Reveals a Heterogenous Population and Reversible Genotype.

Authors:  Mariana Castanheira; S J Ryan Arends; Andrew P Davis; Leah N Woosley; Amira A Bhalodi; Shawn H MacVane
Journal:  mSphere       Date:  2018-09-26       Impact factor: 4.389
View more
  4 in total

Review 1.  In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations.

Authors:  Stamatis Karakonstantis; Petros Ioannou; Diamantis D Kofteridis
Journal:  Infection       Date:  2022-01-04       Impact factor: 3.553

Review 2.  Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam.

Authors:  Matteo Bassetti; Maddalena Peghin; Alessio Mesini; Elio Castagnola
Journal:  Infect Drug Resist       Date:  2020-06-12       Impact factor: 4.003

3.  Molecular Characterization of Carbapenem-Resistant Serratia marcescens Clinical Isolates in a Tertiary Hospital in Hangzhou, China.

Authors:  Qian Xu; Ying Fu; Feng Zhao; Yan Jiang; Yunsong Yu
Journal:  Infect Drug Resist       Date:  2020-04-07       Impact factor: 4.003

4.  Quercetin Rejuvenates Sensitization of Colistin-Resistant Escherichia coli and Klebsiella Pneumoniae Clinical Isolates to Colistin.

Authors:  Yishuai Lin; Ying Zhang; Shixing Liu; Dandan Ye; Liqiong Chen; Na Huang; Weiliang Zeng; Wenli Liao; Yizhou Zhan; Tieli Zhou; Jianming Cao
Journal:  Front Chem       Date:  2021-11-25       Impact factor: 5.221
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.